Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.
Primary Aim:
• To determine safety of stellate ganglion block (SGB) in ARDS
Secondary Aim:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Stellate Ganglion Block (SGB) | Experimental | Clinical Stellate ganglion block |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Stellate Ganglion Block | Procedure | The procedure will be done at the bedside in the ICU without interfering with ongoing treatment. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events related to SGB | Adverse events that can atleast unlikely be attributed to SGB | 3 Months |
| All Adverse events | All adverse events related to COVID-19 | 3 Months |
| Death | Death due to any cause | 3 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of respiratory/ pulmonary function | Change from baseline clinical respiratory/pulmonary function as assessed by change in PF ratio | 3 Months |
| Radiographic criteria | Change from last imaging data obtained prior to SGB procedure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ali R Rezai, MD | West Virginia University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| West Virginia University Rockefeller Neuroscience Institute | Morgantown | West Virginia | 26506 | United States |
Not provided
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
| D011024 | Pneumonia, Viral |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 3 Months |
| Cardiac function | Change from baseline clinical cardiac function as assessed by improvement in arrhythmia as measured by standard of care ECG ( rate, rhythm and / or any aberrant electro physiological changes) | 3 Months |
| D011014 |
| Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |